Carisma Therapeutics to Host Webcast on Phase 1 Clinical Trial of Engineered Macrophage Therapy

June 17, 2022

Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will be hosting a webcast on June 24th at 1:00pm ET to present and discuss the latest data from its landmark, first-in-human chimeric antigen receptor macrophages (CAR-M) study of leading asset CT-0508 for the treatment of HER2 overexpressing solid tumors.

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

January 10, 2022

Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35...

Carisma Therapeutics to Participate in 40th Annual J.P. Morgan Healthcare Conference

January 5, 2022

PHILADELPHIA, Jan. 5, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and Chief Executive Officer of Carisma, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on January 12, 2022, at 7:30 am ET, and will be accessible to...